This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Inflammation; thrombosis	Factor Xa; factor XIa; kallikrein	<i>In vitro</i> and rodent studies suggest desmolaris, a protein from vampire bat saliva, could help treat inflammation and thrombosis. A series of <i>in vitro</i> assays identified desmolaris in vampire bat saliva as a slow, tight, noncompetitive inhibitor of factor Xa and XIa and a partial inhibitor of kallikrein. In mouse models of thrombosis and thromboembolism, desmolaris decreased arterial occlusion and increased survival compared with saline. In mice, injection of desmolaris-treated factor Xa decreased paw inflammation compared with injection of saline-treated factor Xa. Next steps include establishing a partnership for further preclinical and clinical development of desmolaris.	Patent application filed; available for licensing from the NIH Contact: Charlene Sydnor, National Institutes of Health (NIH), Bethesda, Md. e-mail: sydnorc@od.nih.gov	Ma, D. <i>et al. Blood</i> ; published online Oct. 24, 2013; doi:10.1182/blood-2013-08-517474 Contact: Ivo M.B. Francischetti, National Institutes of Health (NIH), Bethesda, Md. e-mail: ifrancischetti@niaid.nih.gov
<i>SciBX</i> 6(46); doi:10.1038/scibx.2013.1328 Published online Dec. 5, 2013				